Psoriasis
main-banner
Psoriasis
M18-816 Enrolling

Moderate to Severe Psoriasis Research Trial (24 Weeks)


Age: 18 Years

Adults at least 18 years old and not more than 65 years of age with a clinical diagnosis of moderate to severe chronic plaque psoriasis with a

disease duration of at least 6 months, may qualify to participate. Individuals must have 10% or more body surface area (BSA) affected by plaque psoriasis, and have no other skin disease which may interfere with assessment of chronic plaque psoriasis.

Participants will receive investigational oral medication (active study drug) or placebo. Study medication and study-related assessments will be provided at no cost. Reimbursement for study-related expenses may be provided.

Study participation will last about 24 weeks and involve about 8 visits to the study centre, plus a follow-up phone call.


Official Title

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of Cedirogant (ABBV-157) in Adult Subjects With Moderate to Severe Psoriasis

ClinicalTrials.gov ID

NCT05044234

Sponsor

AbbVie

Study Description

  • Brief Summary:

    AbbVie

  • Condition or Disease:

    Psoriasis

  • Intervention/Treatment:

    Drug: Cedirogant Drug: Cedirogant Drug: Cedirogant Drug: Placebo
  • Phase:

    Phase 2

  • Ages Eligible for Study:

    18 Years and 65 Years (Adult,Older Adult)

  • Sexes Eligible for Study:

    All

Inclusion Criteria:

– Participants with stable moderate to severe plaque psoriasis of at least 6 months duration and who are candidates for systemic therapy or phototherapy.

Exclusion Criteria:

Primary non-responders to previous anti-IL-17 (e.g., secukinumab, ixekizumab, brodalumab), anti-IL-23 (e.g., guselkumab, tildrakizumab, risankizumab), or anti-IL-12/23 (e.g., ustekinumab) treatment for chronic plaque psoriasis.
Diagnosis of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication exacerbated psoriasis, or new onset guttate psoriasis or any other skin disease which may interfere with assessment of chronic plaque psoriasis.


Participating Locations


Participating Experts

Dr. Rocco Serrao

Dermatologist

Dr. Kim Alexander Papp

Dermatologist

Dr. Charles Lynde

Dermatologist

Dr. Wei Jing Loo

Dermatologist

Dr. Maryam Shayesteh Alam

Dermatologist

Dr. Marni Wiseman

Dermatologist

Dr. Chih-ho Hong

Dermatologist

You May Also Be Interested In

Similar Trials

No Similar Trials Found
about-icon

Learn More About

Psoriasis

Learn More
2022 all rights reserved probity medical research inc
find a trial
filter trials

Filter By Keyword

Trial Name, Intervention and or Treatment, Trial Number, Reference Number, Study Info, Sponsors Phase, and Status.